Literature DB >> 9925541

Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani.

C Petit1, V Yardley, F Gaboriau, J Bolard, S L Croft.   

Abstract

The heat treatment of amphotericin B deoxycholate (Fungizone), which was previously shown to induce superaggregation and decrease the toxicity of the drug to mammalian cells, increased its activity against Leishmania donovani in BALB/c mice, whereas it reduced its toxicity. Heat treatment preserved the activity of Fungizone against L. donovani HU3-infected mouse peritoneal macrophages.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9925541      PMCID： PMC89086     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  Liposomal amphotericin B in the treatment of visceral leishmaniasis.

Authors:  S L Croft; R N Davidson; E A Thornton
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

2.  Physico-chemical properties of the heat-induced 'superaggregates' of amphotericin B.

Authors:  F Gaboriau; M Chéron; L Leroy; J Bolard
Journal:  Biophys Chem       Date:  1997-05-21       Impact factor: 2.352

3.  Liposomal amphotericin B in drug-resistant visceral leishmaniasis.

Authors:  R N Davidson; S L Croft; A Scott; M Maini; A H Moody; A D Bryceson
Journal:  Lancet       Date:  1991-05-04       Impact factor: 79.321

4.  Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes.

Authors:  R R New; M L Chance; S Heath
Journal:  J Antimicrob Chemother       Date:  1981-11       Impact factor: 5.790

5.  In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating.

Authors:  C Petit; M Chéron; V Joly; J M Rodrigues; J Bolard; F Gaboriau
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

6.  Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys.

Authors:  J D Berman; W L Hanson; W L Chapman; C R Alving; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

7.  Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions.

Authors:  J Seaman; C Boer; R Wilkinson; J de Jong; E de Wilde; E Sondorp; R Davidson
Journal:  Clin Infect Dis       Date:  1995-07       Impact factor: 9.079

Review 8.  Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.

Authors:  R Janknegt; S de Marie; I A Bakker-Woudenberg; D J Crommelin
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

9.  Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes.

Authors:  P Legrand; E A Romero; B E Cohen; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

10.  Activity of amphotericin B cholesterol dispersion (Amphocil) in experimental visceral leishmaniasis.

Authors:  J D Berman; G Ksionski; W L Chapman; V B Waits; W L Hanson
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191
View more
  17 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana.

Authors:  Hamdan I Al-Mohammed; Michael L Chance; Paul A Bates
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Heat treatment of amphotericin b modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits.

Authors:  E H Kwong; M Ramaswamy; E A Bauer; S C Hartsel; K M Wasan
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  The effect of serum albumin on amphotericin B aggregate structure and activity.

Authors:  S C Hartsel; E Bauer; E H Kwong; K M Wasan
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

5.  Activity and kinetics of dissociation and transfer of amphotericin B from a novel delivery form.

Authors:  B Baas; K Kindt; A Scott; J Scott; P Mikulecky; S C Hartsel
Journal:  AAPS PharmSci       Date:  1999

6.  Antileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex.

Authors:  Abeer H A Mohamed-Ahmed; Karin Seifert; Vanessa Yardley; Hollie Burrell-Saward; Stephen Brocchini; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

7.  Anti-trypanosomatid activity of ceragenins.

Authors:  Diana Lara; Yanshu Feng; Julia Bader; Paul B Savage; Rosa A Maldonado
Journal:  J Parasitol       Date:  2010-06       Impact factor: 1.276

8.  Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.

Authors:  J A Sánchez-Brunete; M A Dea; S Rama; F Bolás; J M Alunda; R Raposo; M T Méndez; S Torrado-Santiago; J J Torrado
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B.

Authors:  Malika Larabi; Vanessa Yardley; Philippe M Loiseau; Martine Appel; Philippe Legrand; Annette Gulik; Christian Bories; Simon L Croft; Gillian Barratt
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

10.  Influence of the freeze-drying process on the physicochemical and biological properties of pre-heated amphotericin B micellar systems.

Authors:  Scheyla D V S Siqueira; Miguel A Silva-Filho; Christian A Silva; Ivonete B Araújo; Acarilia E Silva; Matheus F Fernandes-Pedrosa; Anselmo G Oliveira; E Sócrates T Egito
Journal:  AAPS PharmSciTech       Date:  2014-02-08       Impact factor: 3.246
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.